Additionally, the abundance of tumor-infiltrating lymphocytes (TILs) significantly correlates with the prognosis of trastuzumab-treated patients with MBC [8], further supporting an important interaction between host immunity and anti-HER2 therapy. This evidence concerns the gene ERBB2 and neoplasm.